PEG-rhG-CSF初级预防同步放化疗后中性粒细胞减少的有效性观察

doi:10.3760/cma.j.cn113030-20200324-00131

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the efficacy and safety of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia. Methods In this single-center, open-label, single-arm clinical observation, the efficacy of PEG-rhG-CSF in the primary prevention of neutropenia after concurrent chemoradiotherapy in 58 patients admitted to Tianjin Medical University Cancer Institute and Hospital from June 2018 to June 2019 was evaluated. Results During the whole concurrent chemoradiotherapy, chemotherapy delay occurred in 6 patients (10%). Three patients (5%) had delayed concurrent chemotherapy due to leukopenia or neutropenia. The completion rate of chemotherapy cycle was 94.6%(106/112). Radiotherapy delay occurred in 10 patients (17%) including 2 patients (3%) of delayed radiotherapy due to leukopenia or neutropenia. No patient developed febrile neutropenia (FN). Subgroup analysis found that after completing 1 cycle of concurrent chemoradiotherapy, the incidence rates of grade 4 leukopenia and neutropenia were both 0. After completing 2 cycles of concurrent chemoradiotherapy, the incidence rates of grade 4 leukopenia and neutropenia were 0 and 2%. Conclusion During the chemoradiotherapy, application of PEG-rhG-CSF in the primary preventation can significantly reduce the incidence of FN, grade 4 leukopenia and neutropenia, which is beneficial to ensure the smooth progress of concurrent chemoradiotherapy.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Chen Yang
	Wang Wei
	Zhang Ruiping
	Liu Ransheng
	Zhang Aixu
	Wang Zhizhen

Key words： PEG-rhG-CSF Primary prevention Concurrent chemoradiotherapy Neutropenia

Received: 24 March 2020

Corresponding Authors: Wang Zhizhen, Email:965458069@qq.com

Cite this article:

Chen Yang,Wang Wei,Zhang Ruiping et al. Efficacy of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia[J]. Chinese Journal of Radiation Oncology, 2021, 30(1): 66-70.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200324-00131 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I1/66

[1] Lin JC, Jan JS, Hsu CY, et al. Phase Ⅲ study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overall and progression-free survival[J]. J Clin Oncol, 2003, 21(4):631-637. DOI:10.1200/JCO.2003.06.158.
[2] Pearcey R, Brundage M, Drouin P, et al. Phase Ⅲ trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix[J]. J Clin Oncol, 2002, 20(4):966-972. DOI:10.1200/JCO.2002.20.4.966.
[3] Curran WJ, Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer:randomized phase Ⅲ trial RTOG 9410[J]. J Natl Cancer Inst, 2011, 103(19):1452-1460. DOI:10.1093/jnci/djr325.
[4] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA, 1999, 281(17):1623-1627. DOI:10.1001/jama.281.17.1623.
[5] Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia[J]. Cochrane Database Syst Rev, 2014(10):CD003039. DOI:10.1002/14651858. CD003039.pub2.
[6] Punnapuzha S, Edemobi PK, Elmoheen A. Febrile neutropenia[M]. Treasure Island (FL):StatPearls, 2020.
[7] Hadji P, Kostev K, Schroder-Bernhardi D, et al. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany[J]. Int J Clin Pharmacol Ther, 2012, 50(4):281-289. DOI:10.5414/cp201633.
[8] Wen TJ, Wen YW, Chien CR, et al. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin′s lymphoma patients under Taiwan′s national health insurance system[J]. J Eval Clin Pract, 2017, 23(2):288-293. DOI:10.1111/jep.12597. Epub 2016 Aug 4.
[9] Arvedson T, O′Kelly J, Yang BB. Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor[J]. BioDrugs, 2015, 29(3):185-198. DOI:10.1007/s40259-015-0127-4.
[10] McMillan MT, Ojerholm E, Verma V, et al. Radiation treatment time and overall survival in locally advanced non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 98(5):1142-1152. DOI:10.1016/j.ijrobp.2017.04.004.
[11] O′Rourke N, Roque IFM, Farre-Bernado N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2010(6):CD002140.
[12] Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010):a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27):2796-2803. DOI:10.1200/JCO.2018.79.1483.
[13] Videtic GM, Fung K, Tomiak AT, et al. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control[J]. Lung Cancer, 2001, 33(2-3):249-258. DOI:10.1016/s0169-5002(00)00240-3.
[14] Du R, Hu P, Liu Q, et al. Granulocyte colony-stimulating factor treatment during radiotherapy is associated with survival benefit in patients with lung cancer[J]. Technol Cancer Res Treat, 2018, 17:1533033818816076. DOI:10.1177/1533033818816076.
[15] Wu FP, Wang J, Wang H, et al. Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia[J]. Exp Ther Med, 2015, 9(3):761-765. DOI:10.3892/etm.2014.2160. Epub 2014 Dec 30.
[16] Almenar D, Mayans J, Juan O, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor:patterns of use and neutropenia-related outcomes in cancer patients in Spain-results of the LEARN study[J]. Eur J Cancer Care (Engl), 2009, 18(3):280-286. DOI:10.1111/j.1365-2354.2008.00959. x.
[17] 李惠平,樊征夫,郑虹,等. 聚乙二醇化重组人粒细胞集落刺激因子初级与次级预防化疗后中性粒细胞减少的有效性和安全性临床研究[J]. 中国肿瘤临床, 2019, 46(14):739-744. DOI:CNKI:SUN:ZGZL.0.2019-14-010.
Li HP, Fan ZF, Zheng H, et al. Clinical study on the efficacy and safety of pegylated recombinant human granulocyte colony stimulating factor in primary and secondary prevention of neutropenia after chemotherapy[J]. Chin J Clin Oncol, 2019, 46(14):739-744. DOI:CNKI:SUN:ZGZL.0.2019-14-010.
[18] Liu F, Du Y, Cai B, et al. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy[J]. J Cancer Res Ther, 2017, 13(5):790-795. DOI:10.4103/jcrt. JCRT_320_17.
[19] 刘芳,俞伟,梁岚清,等. 聚乙二醇重组人粒细胞集落刺激因子预防头颈部肿瘤同步放化疗后中性粒细胞减少症的研究[J]. 中国临床保健杂志, 2015(4):386-389. DOI:10.3969/J.issn.1672-6790.2015.04.018.
Liu F, Yu W, Liang LQ, et al. Prevention of neutropenia after concurrent chemoradiotherapy for head and neck tumors with polyethylene glycol recombinant human granulocyte colony stimulating factor[J]. Chin J Clin Healthcare, 2015(4):386-389. DOI:10.3969/J.issn.1672-6790.2015.04.018.